Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Study protocol

Rationale and design of ASPIRE-ICU: a prospective cohort study on the incidence and predictors of Staphylococcus aureus and Pseudomonas aeruginosa pneumonia in the ICU

Authors: Fleur P. Paling, Darren P. R. Troeman, Martin Wolkewitz, Rubana Kalyani, Daniël R. Prins, Susanne Weber, Christine Lammens, Leen Timbermont, Herman Goossens, Surbhi Malhotra-Kumar, Frangiscos Sifakis, Marc J. M. Bonten, Jan A. J. W. Kluytmans

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

The epidemiology of ICU pneumonia caused by Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) is not fully described, but is urgently needed to support the development of effective interventions. The objective of this study is to estimate the incidence of S. aureus and P. aeruginosa ICU pneumonia and to assess its association with patient-related and contextual risk factors.

Methods

ASPIRE-ICU is a prospective, observational, multi-center cohort study nested within routine surveillance among ICU patients in Europe describing the occurrence of S. aureus and P. aeruginosa ICU pneumonia. Two thousand (2000) study cohort subjects will be enrolled (50% S. aureus colonized) in which specimens and data will be collected. Study cohort subjects will be enrolled from a larger surveillance population, in which basic surveillance data is captured. The primary outcomes are the incidence of S. aureus ICU acquired pneumonia and the incidence of P. aeruginosa ICU acquired pneumonia through ICU stay.
The analysis will include advanced survival techniques (competing risks and multistate models) for each event separately as well as for the sub-distribution of ICU pneumonia to determine independent association of outcomes with risk factors.. A risk prediction model will be developed to quantify the risk for acquiring S. aureus or P. aeruginosa ICU pneumonia during ICU stay by using a composite score of independent risk factors.

Discussion

The diagnosis of pathogen-specific ICU pneumonia is difficult, however, the criteria used in this study are objective and comparable to those in the literature.

Trial registration

This study is registered on clinicaltrials.gov under identifier NCT02413242.
Appendix
Available only for authorised users
Literature
2.
go back to reference Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. EPIC international advisory committee. JAMA. 1995;274:639–44. Available: http://www.ncbi.nlm.nih.gov/pubmed/7637145.CrossRefPubMed Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. EPIC international advisory committee. JAMA. 1995;274:639–44. Available: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​7637145.CrossRefPubMed
5.
go back to reference Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus Aureus-induced pneumonia. Antimicrob agents Chemother. Am Soc Microbiol (ASM). 2014;58:1108–17. doi:10.1128/AAC.02190-13. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus Aureus-induced pneumonia. Antimicrob agents Chemother. Am Soc Microbiol (ASM). 2014;58:1108–17. doi:10.​1128/​AAC.​02190-13.
6.
7.
go back to reference Kostyanev T, Bonten MJM, O’Brien S, Steel H, Ross S, François B, et al. The innovative medicines Initiative’s new drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother Oxford University Press. 2016;71:290–5. doi:10.1093/jac/dkv339.CrossRef Kostyanev T, Bonten MJM, O’Brien S, Steel H, Ross S, François B, et al. The innovative medicines Initiative’s new drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother Oxford University Press. 2016;71:290–5. doi:10.​1093/​jac/​dkv339.CrossRef
8.
go back to reference François B, Chastre J, Eggiman P, Laterre P-F, Torres A, Sanchez M, et al. The SAATELLITE and EVADE clinical studies within the COMBACTE consortium: a public–private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent Nosocomial pneumonia: table 1. Clin Infect Dis. 2016;63:S46–51. doi:10.1093/cid/ciw245.CrossRefPubMed François B, Chastre J, Eggiman P, Laterre P-F, Torres A, Sanchez M, et al. The SAATELLITE and EVADE clinical studies within the COMBACTE consortium: a public–private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent Nosocomial pneumonia: table 1. Clin Infect Dis. 2016;63:S46–51. doi:10.​1093/​cid/​ciw245.CrossRefPubMed
11.
go back to reference Ziakas PD, Anagnostou T, Mylonakis E. The prevalence and significance of methicillin-resistant Staphylococcus Aureus colonization at admission in the general ICU setting: a meta-analysis of published studies. Crit Care Med. 2014;42:433–44. doi:10.1097/CCM.0b013e3182a66bb8.CrossRefPubMed Ziakas PD, Anagnostou T, Mylonakis E. The prevalence and significance of methicillin-resistant Staphylococcus Aureus colonization at admission in the general ICU setting: a meta-analysis of published studies. Crit Care Med. 2014;42:433–44. doi:10.​1097/​CCM.​0b013e3182a66bb8​.CrossRefPubMed
12.
go back to reference Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus Aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis. 2004;39:776–82. doi:10.1086/422997.CrossRefPubMed Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus Aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis. 2004;39:776–82. doi:10.​1086/​422997.CrossRefPubMed
13.
go back to reference Kollef MH, Chastre J, Fagon J-Y, François B, Niederman MS, Rello J, et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas Aeruginosa. Crit Care Med. 2014;42:2178–87. doi:10.1097/CCM.0000000000000510.CrossRefPubMed Kollef MH, Chastre J, Fagon J-Y, François B, Niederman MS, Rello J, et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas Aeruginosa. Crit Care Med. 2014;42:2178–87. doi:10.​1097/​CCM.​0000000000000510​.CrossRefPubMed
Metadata
Title
Rationale and design of ASPIRE-ICU: a prospective cohort study on the incidence and predictors of Staphylococcus aureus and Pseudomonas aeruginosa pneumonia in the ICU
Authors
Fleur P. Paling
Darren P. R. Troeman
Martin Wolkewitz
Rubana Kalyani
Daniël R. Prins
Susanne Weber
Christine Lammens
Leen Timbermont
Herman Goossens
Surbhi Malhotra-Kumar
Frangiscos Sifakis
Marc J. M. Bonten
Jan A. J. W. Kluytmans
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2739-4

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue